Silencing the long noncoding RNA, TINCR, a molecular sponge of miR‑335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression

  • Authors:
    • Rui Li
    • Yue Wang
    • Yuexun Xu
    • Xiaoli He
    • Yali Li
  • View Affiliations

  • Published online on: September 10, 2019     https://doi.org/10.3892/ijo.2019.4875
  • Pages: 1110-1124
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aberrant terminal differentiation‑induced noncoding RNA (TINCR) expression has been identified in multiple human cancer types and is functionally significant in cancer progression. However, to the best of our knowledge, no reported studies have investigated the expression pattern and precise role of TINCR in epithelial ovarian cancer (EOC). Here, TINCR expression levels in EOC tissues and cell lines were determined by reverse transcription‑quantitative polymerase chain reaction. Cell Counting Kit‑8 assays, flow cytometric analysis, Transwell migration and invasion assays, and in vivo xenograft experiments were performed to determine the influence of TINCR on the malignant phenotype of EOC cells in vitro and in vivo. The molecular mechanisms associated with the tumor‑promoting roles of TINCR during EOC progression were elucidated using a series of experiments. TINCR expression was higher in EOC tissues and cell lines compared with normal cells. An analysis of the association between TINCR expression and clinicopathological characteristics showed that increased TINCR expression was closely related to tumor size, FIGO stage, and lymphatic metastasis. In addition, the overall survival rates of EOC patients with high TINCR expression levels were lower than in those with low TINCR expression levels. Functional experiments showed that TINCR deficiency attenuated the proliferation, migration, and invasion of EOC cells in vitro and hindered EOC tumor growth in vivo. In addition, EOC cell apoptosis increased after TINCR knockdown. Mechanistically, TINCR was shown to function as a sponge of microRNA‑335 (miR‑335) in EOC cells, thereby regulating fibroblast growth factor 2 (FGF2) expression. miR‑335 inhibition partially counteracted the effect of TINCR knockdown on the aggressive behavior of EOC cells. This study showed, for the first time to the best of our knowledge, that silencing TINCR, which interacts with miR‑335, inhibited EOC progression in vitro and in vivo by decreasing FGF2 expression. Hence, this lncRNA could be a potential prognostic biomarker and effective target for therapeutic intervention in EOC.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI

2 

Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N and Sessa C: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(Suppl 6): vi24–vi32. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Lupia M and Cavallaro U: Ovarian cancer stem cells: Still an elusive entity? Mol Cancer. 16:642017. View Article : Google Scholar : PubMed/NCBI

4 

La Vecchia C: Ovarian cancer: Epidemiology and risk factors. Eur J Cancer Prev. 26:55–62. 2017. View Article : Google Scholar

5 

Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks E, Harrington P, Ramus SJ, et al: Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res. 21:652–657. 2015. View Article : Google Scholar :

6 

Karnezis AN and Cho KR: Preclinical models of ovarian cancer: Pathogenesis, problems, and implications for prevention. Clin Obstet Gynecol. 60:789–800. 2017. View Article : Google Scholar : PubMed/NCBI

7 

Wang X, Ivan M and Hawkins SM: The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer. Gynecol Oncol. 147:481–487. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu J: Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 333:213–221. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM and Zheng SS: Long non-coding RNA MALAT-1 over-expression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 29:1810–1816. 2012. View Article : Google Scholar

10 

Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-Lail R, Fellig Y, Degroot N, Galun E and Hochberg A: The oncofetal H19 RNA connection: Hypoxia, p53 and cancer. Biochim Biophys Acta. 1803:443–451. 2010. View Article : Google Scholar : PubMed/NCBI

11 

ENCODE Project Consortium; Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, et al: Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 447:799–816. 2007. View Article : Google Scholar : PubMed/NCBI

12 

Gutschner T and Diederichs S: The hallmarks of cancer: A long non-coding RNA point of view. RNA Biol. 9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, Cheunsuchon P, Louis DN and Klibanski A: Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res. 70:2350–2358. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, Chen K, Xiao H, Li H, Tang K, et al: Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression. Mol Cancer Ther. 13:3086–3097. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Chen Y, Du H, Bao L and Liu W: LncRNA PVT1 promotes ovarian cancer progression by silencing miR-214. Cancer Biol Med. 15:238–250. 2018. View Article : Google Scholar : PubMed/NCBI

16 

Yan H, Silva MA, Li H, Zhu L, Li P, Li X, Wang X, Gao J, Wang P and Zhang Z: Long noncoding RNA DQ786243 interacts with miR-506 and promotes progression of ovarian cancer through targeting cAMP responsive element binding protein 1. J Cell Biochem. 119:9764–9780. 2018. View Article : Google Scholar : PubMed/NCBI

17 

Zhang C, Wang M, Shi C, Shi F and Pei C: Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway. Biosci Trends. 12:309–316. 2018. View Article : Google Scholar : PubMed/NCBI

18 

Qu C, Dai C, Guo Y, Qin R and Liu J: Long noncoding RNA SNHG15 serves as an oncogene and predicts poor prognosis in epithelial ovarian cancer. Onco Targets Ther. 12:101–111. 2019. View Article : Google Scholar

19 

Li J, Feng L, Tian C, Tang YL, Tang Y and Hu FQ: Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 22:8135–8144. 2018.PubMed/NCBI

20 

Shi C and Wang M: LINC01118 modulates paclitaxel resistance of epithelial ovarian cancer by regulating miR-134/ABCC1. Med Sci Monit. 24:8831–8839. 2018. View Article : Google Scholar : PubMed/NCBI

21 

Xue Z, Zhu X and Teng Y: Long noncoding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer. Mol Med Rep. 18:5173–5181. 2018.PubMed/NCBI

22 

Wang C, Qi S, Xie C, Li C, Wang P and Liu D: Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p. J Gynecol Oncol. 29:e992018. View Article : Google Scholar : PubMed/NCBI

23 

Wang YS, Ma LN, Sun JX, Liu N and Wang H: Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis. Eur Rev Med Pharmacol Sci. 21:3169–3175. 2017.PubMed/NCBI

24 

Qin Z, Zheng X and Fang Y: Long noncoding RNA TMPO-AS1 promotes progression of non-small cell lung cancer through regulating its natural antisense transcript TMPO. Biochem Biophys Res Commun. 516:486–493. 2019. View Article : Google Scholar : PubMed/NCBI

25 

Montavon Sartorius C, Mirza U, Schotzau A, Mackay G, Fink D, Hacker NF and Heinzelmann-Schwarz V: Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers. Cancer Manag Res. 10:4709–4718. 2018. View Article : Google Scholar : PubMed/NCBI

26 

Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, Lu L, Liu C, Yi JS, Zhang H, et al: The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol cell. 52:101–112. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Men Y, Fan Y, Shen Y, Lu L and Kallen AN: The steroidogenic acute regulatory protein (StAR) is regulated by the H19/let-7 Axis. Endocrinology. 158:402–409. 2017. View Article : Google Scholar :

28 

Zuckerwise L, Li J, Lu L, Men Y, Geng T, Buhimschi CS, Buhimschi IA, Bukowski R, Guller S, Paidas M and Huang Y: H19 long noncoding RNA alters trophoblast cell migration and invasion by regulating TβR3 in placentae with fetal growth restriction. Oncotarget. 7:38398–38407. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Zheng Y, Lv P, Wang S, Cai Q, Zhang B and Huo F: LncRNA PLAC2 upregulates p53 to induce hepatocellular carcinoma cell apoptosis. Gene. 712:1439442019. View Article : Google Scholar : PubMed/NCBI

30 

Yang H, Fu G, Liu F, Hu C, Lin J, Tan Z, Fu Y, Ji F and Cao M: LncRNA THOR promotes tongue squamous cell carcinomas by stabilizing IGF2BP1 downstream targets. Biochimie. 165:9–18. 2019. View Article : Google Scholar : PubMed/NCBI

31 

Dong L, Ding H, Li Y, Xue D and Liu Y: LncRNA TINCR is associated with clinical progression and serves as tumor suppressive role in prostate cancer. Cancer Manag Res. 10:2799–2807. 2018. View Article : Google Scholar : PubMed/NCBI

32 

Zhang X, Yao J, Shi H, Gao B and Zhang L: LncRNA TINCR/microRNA-107/CD36 regulates cell proliferation and apoptosis in colorectal cancer via PPAR signaling pathway based on bioinformatics analysis. Biol Chem. 400:663–675. 2019. View Article : Google Scholar

33 

Zhang ZY, Lu YX, Zhang ZY, Chang YY, Zheng L, Yuan L, Zhang F, Hu YH, Zhang WJ and Li XN: Loss of TINCR expression promotes proliferation, metastasis through activating EpCAM cleavage in colorectal cancer. Oncotarget. 7:22639–22649. 2016.PubMed/NCBI

34 

Tian F, Xu J, Xue F, Guan E and Xu X: TINCR expression is associated with unfavorable prognosis in patients with hepatocellular carcinoma. Biosci Rep. 37:BSR201703012017. View Article : Google Scholar : PubMed/NCBI

35 

Liu Y, Du Y, Hu X, Zhao L and Xia W: Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer. BMC Cancer. 18:3672018. View Article : Google Scholar : PubMed/NCBI

36 

Chen Z, Liu H, Yang H, Gao Y, Zhang G and Hu J: The long noncoding RNA, TINCR, functions as a competing endogenous RNA to regulate PDK1 expression by sponging miR-375 in gastric cancer. Onco Targets Ther. 10:3353–3362. 2017. View Article : Google Scholar :

37 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar

38 

Chan JJ and Tay Y: Noncoding RNA: RNA regulatory networks in cancer. Int J Mol Sci. 19:pii: E13102018. View Article : Google Scholar

39 

Cao J, Cai J, Huang D, Han Q, Chen Y, Yang Q, Yang C, Kuang Y, Li D and Wang Z: miR-335 represents an independent prognostic marker in epithelial ovarian cancer. Am J Clin Pathol. 141:437–442. 2014. View Article : Google Scholar : PubMed/NCBI

40 

Liu R, Guo H and Lu S: MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2. Cancer Med. 7:4598–4609. 2018. View Article : Google Scholar : PubMed/NCBI

41 

Cao J, Cai J, Huang D, Han Q, Yang Q, Li T, Ding H and Wang Z: miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol Rep. 30:701–706. 2013. View Article : Google Scholar : PubMed/NCBI

42 

Lau MT, So WK and Leung PC: Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 8:e590832013. View Article : Google Scholar : PubMed/NCBI

43 

De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, et al: Gene expression profiling of advanced ovarian cancer: Characterization of a molecular signature involving fibroblast growth factor 2. Oncogene. 23:8171–8183. 2004. View Article : Google Scholar : PubMed/NCBI

44 

Yu WD, Wang H, He QF, Xu Y and Wang XC: Long noncoding RNAs in cancer-immunity cycle. J Cell Physiol. 233:6518–6523. 2018. View Article : Google Scholar : PubMed/NCBI

Vallone C, Rigon G, Gulia C, Baffa A, Votino R, Morosetti G, Zaami S, Briganti V, Catania F, Gaffi M, et al: Non-coding RNAs and endometrial cancer. Genes (Basel). 9:pii: E1872018. View Article : Google Scholar

45 

Chen X, Sun Y, Cai R, Wang G, Shu X and Pang W: Long noncoding RNA: Multiple players in gene expression. BMB Rep. 51:280–289. 2018. View Article : Google Scholar : PubMed/NCBI

46 

Chu ZP, Dai J, Jia LG, Li J, Zhang Y, Zhang ZY and Yan P: Increased expression of long noncoding RNA HMMR-AS1 in epithelial ovarian cancer: An independent prognostic factor. Eur Rev Med Pharmacol Sci. 22:8145–8150. 2018.PubMed/NCBI

47 

Hu X, Li Y, Kong D, Hu L, Liu D and Wu J: Long noncoding RNA CASC9 promotes LIN7A expression via miR-758-3p to facilitate the malignancy of ovarian cancer. J Cell Physiol. 234:10800–10808. 2019. View Article : Google Scholar

48 

Liu X, Wen J, Wang H and Wang Y: Long non-coding RNA LINC00460 promotes epithelial ovarian cancer progression by regulating microRNA-338-3p. Biomed Pharmacother. 108:1022–1028. 2018. View Article : Google Scholar : PubMed/NCBI

49 

Liu S, Liu Y, Lu Q, Zhou X, Chen L and Liang W: The lncRNA TUG1 promotes epithelial ovarian cancer cell proliferation and invasion via the WNT/β-catenin pathway. Onco Targets Ther. 11:6845–6851. 2018. View Article : Google Scholar :

50 

Wang J, Xu W, He Y, Xia Q and Liu S: LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN. Inflamm Res. 67:927–936. 2018. View Article : Google Scholar : PubMed/NCBI

51 

Gordon MA, Babbs B, Cochrane DR, Bitler BG and Richer JK: The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 58:196–205. 2019. View Article : Google Scholar

52 

Litwin M, Radwańska A, Paprocka M, Kieda C, Dobosz T, Witkiewicz W and Baczyńska D: The role of FGF2 in migration and tubulogenesis of endothelial progenitor cells in relation to pro-angiogenic growth factor production. Mol Cell Biochem. 410:131–142. 2015. View Article : Google Scholar : PubMed/NCBI

53 

Xu M, Gu M, Zhang K, Zhou J, Wang Z and Da J: miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2. Diagn Pathol. 10:242015. View Article : Google Scholar : PubMed/NCBI

54 

Sahores A, Figueroa V, May M, Liguori M, Rubstein A, Fuentes C, Jacobsen BM, Elía A, Rojas P, Sequeira GR, et al: Increased high molecular weight FGF2 in endocrine-resistant breast cancer. Horm Cancer. 9:338–348. 2018. View Article : Google Scholar : PubMed/NCBI

55 

Zhang X, Xu J, Jiang T, Liu G, Wang D and Lu Y: MicroRNA-195 suppresses colorectal cancer cells proliferation via targeting FGF2 and regulating Wnt/β-catenin pathway. Am J Cancer Res. 6:2631–2640. 2016.

56 

Deng ZH, Cao HQ, Hu YB, Wen JF and Zhou JH: TRX is up-regulated by fibroblast growth factor-2 in lung carcinoma. APMIS. 119:57–65. 2011. View Article : Google Scholar

57 

Feng QL, Shi HR, Qiao LJ and Zhao J: Expression of hSef and FGF-2 in epithelial ovarian tumor. Zhonghua Zhong Liu Za Zhi. 33:770–774. 2011.In Chinese.

58 

Whitworth MK, Backen AC, Clamp AR, Wilson G, McVey R, Friedl A, Rapraeger AC, David G, McGown A, Slade RJ, et al: Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res. 11:4282–4288. 2005. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November 2019
Volume 55 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, R., Wang, Y., Xu, Y., He, X., & Li, Y. (2019). Silencing the long noncoding RNA, TINCR, a molecular sponge of miR‑335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression. International Journal of Oncology, 55, 1110-1124. https://doi.org/10.3892/ijo.2019.4875
MLA
Li, R., Wang, Y., Xu, Y., He, X., Li, Y."Silencing the long noncoding RNA, TINCR, a molecular sponge of miR‑335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression". International Journal of Oncology 55.5 (2019): 1110-1124.
Chicago
Li, R., Wang, Y., Xu, Y., He, X., Li, Y."Silencing the long noncoding RNA, TINCR, a molecular sponge of miR‑335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression". International Journal of Oncology 55, no. 5 (2019): 1110-1124. https://doi.org/10.3892/ijo.2019.4875